#1
|
|||
|
|||
Ïîñòîÿííîå ïîâûøåíèå ÑÐÁ. Òåìïåðàòóðà.
Çäðàâñòâóéòå óâàæàåìûå âðà÷è. Ïîìîãèòå ïîæàëóéñòà ðàçîáðàòüñÿ ÷òî ñ ðåáåíêîì. Íå çíàþ êóäà îáðàùàòüñÿ êàê åìó ïîìî÷ü!
Ïåðâûé ðàç ðåáåíîê (2ãîäà) çàáîëåë â èþíå 2019ã. Îêîëî äâóõ íåäåëü áûëà òåìïåðàòóðà 37,5 òîëüêî â âå÷åðíåå âðåìÿ. Ïðè îñìîòðå âñå íîðì. Ïîñòàâèëè îðâè. ×åðåç 2 íåäåëè òåìïåðàòóðà ïîäíÿëàñü ïîä 40. Ïðè îñìîòðå âûñëóøàëè õðèïû â ëåãêèõ. Ïîñòàâèëè ïíåâìîíèþ êëèíè÷åñêè. ÊÀÊ áûë íîðìàëüíûé. Ñ ðåàê áåëîê 30. (Ðåçóëüòàòû íå ñîõðàíèëèñü) Ëå÷èëè öåôòðèàêñîíîì.  îêòÿáðå îïÿòü ïîÿâèëàñü òåìïåðàòóðà ïî âå÷åðàì 37.0-37,5. Äåðæàëàñü òðè íåäåëè. Ïðè îñìîòðå øóìû â ñåðäöå. Îñòàëüíîå íîðì. ×åðåç òðè íåäåëè òåìïåðàòóðà ïîä 40. Ñ ðåàê áåëîê 28. Êëèíèêà: ñîý27(ðåçóëüòàò ïðèëàãàþ) Ãîñïèòàëèçàöèÿ. Àíòèáèîòèêè. Ñìóòèëî, ÷òî ïîñëå ïåðâîé èíúåêöèè àíòèáèîòèêà ÷åðåç 9÷àñîâ âçÿëè àíàëèç êðîâè, è Ñ ðåàê áåëîê áûë óæå â íîðìå. Ñåðäöå îáñëåäîâàëè, çàêëþ÷åíèå -ôóíêöèîíàëüíûé øóì Óçè ïî÷åê, áðþøíîé ïîëîñòè - íîðì Ëîð - íîðì Ðåíòãåí ëåãêèõ-íîðì Âûÿâèëè â àíàëèçàõ äíê ÂÃ× 6 è ñêàçàëè, ÷òî âî âñåì âèíîâàò îí. Ñî 2ãî äåêàáðÿ ñíîâà òåìïåðàòóðà 37.0-38.1 â âå÷åðíåå âðåìÿ. Ñî 2-4 íîÿáðÿ áûë íåáîëüøîé íàñìîðê, êîíúþíêòèâèò ãíîéíûé, îäèí ðàç ïîæàëîâàëàñü íà óõî. Ëå÷èëè ìåñòíî. Ãîðëî íîðìàëüíîå, ëèìôîóçëû íå óâåëè÷åíû. Ñ 5ãî ÷èñëà íîñ äûøèò îòëè÷íî, áåç îòäåëÿåìîãî, ãëàçà çäîðîâû, õðèïîâ â ëåãêèõ íåò. Íàñòðîåíèå õîðîøåå, óòîìëÿåìîñòü ïîâûøåííàÿ. 9ãî ñäàëè àíàëèçû è òàì ñ ðåàê áåëîê ñíîâà âûñîêèé! À êëèíèêà â íîðìå. Ðåçóëüòàò ïðèëàãàþ. Ïîäñêàæèòå ïîæàëóéñòà ÷òî äåëàòü? |
#2
|
|||
|
|||
Îáñëåäîâàíà íà âèðóñû.. Öìâ è âã÷6 ðàíåå ïåðåíåñåííûå. Ñâåæåãî íè÷åãî íåò
|
#3
|
||||
|
||||
Ö-ðåàêòèâíûé áeëîê ìîæåò ïîâûøàòüñÿ ïðè ëþáîì âîñïàëèòåëüíîì ïðîöåññå ó ðåáåíêà, íå îáÿçàòåëüíî áàê. èíôåêöèè, îí ïîâûøàåòñÿ ïåðâûì è óõîäèò ÷åðåç ñóòêè/äâîå, à ÑÎÅ è èçìåíåíèÿ â êðîâè âîçíèêàþò ïîçæå
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#4
|
||||
|
||||
Äà è â ïðèíöèïå Âû ïîêà îïèñûâàåòå ÷åðåäó âèðóñíûõ èíôåêöèé ó ðåáåíêà, ñìåíÿþùèõ äðóã äðóãà, è âîçíèêàþùèõ â íîðìå ó ðåáåíêà òàêîãî âîçðàñòà. Åñëè íåò ðåöèäèâèðóþùèõ ãíîéíûõ èíôåêöèé, ñïîêîéíî æèòü, íàáëþäàòü, ëå÷èòü èíôåêöèè êàê â ×ÀÂÎ ïî ÎÐÂÈ.
https://forums.rusmedserv.com/showthread.php?t=25432 Öåëåñîîáðàçíîñòü íàçíà÷åíèÿ àá â ïðåäûäóùèõ ñèòóàöèÿõ ìîãëà áûòü ïîä âîïðîñîì, íî äàæå, åñëè áûëà îäíà ïíåâìîíèÿ, ÷òî-òî èñêàòü ó ðåáåíêà ïðè íîðìàëüíîì ñàìî÷óâñòâèè íåò ñìûñëà. Òåìïåðàòóðà äî 37,5 òàêæå âàðèàíò íîðìû.  ä/ñ õîäèò?
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷ |
#5
|
|||
|
|||
Ñïàñèáî.  ä/ñàä íå õîäèò. Êàê æå â áóäóùåì èçáåæàòü à/á òåðàïèè åñëè ñëó÷àé áóäåò ïîâòîðÿòüñÿ? Êàê èçáåæàòü ðåçêîãî ïîäúåìà òåìïåðàòóðû? Ïðè ñóáôåáðèëèòåòå ó íåå ñòðàäàåò îáùåå ñàìî÷óâñòâèå, ïîýòîìó äóìàþ äëÿ íåå ýòî íå íîðìà.
Ñòîèò ëè ñäàòü ïðîêàëüöèòîíèí? Îáñëåäîâàòüñÿ íà âèðóñû? |
#6
|
||||
|
||||
Healthy persons generally have C-reactive protein levels no higher than 10 mg per L. In patients with invasive acute bacterial infections, the C-reactive protein level tends to range from 150 to 350 mg per L. In patients with viral infections, the C-reactive protein value is usually much lower, less than 20 to 40 mg per L. However, this distinction is not absolute. C-reactive protein values greater than 100 mg per L can occur in uncomplicated infections caused by adenovirus, cytomegalovirus, and the viruses that cause influenza, measles and mumps. C-reactive protein determination cannot be used to classify the precise microbial etiology of an infection, but it is useful in conjunction with other tests in distinguishing between viral and bacterial infection.
.... Studies of C-reactive protein values in autoimmune and rheumatologic diseases demonstrate better correlation than erythrocyte sedimentation rate with severity of clinical disease activity. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] äàííûõ çà àâòîèìóííîå èëè ðåâìàòîëîãè÷åñêîå çàáîëåâàíèå íåò.Ñêîðåå âñåãî ÷åðåäà ÎÐÂÈ , ïîñëå êîò.ìîæåò ñîõðàíÿòüñÿ ñóáôèáðèëèòåò |
#7
|
|||
|
|||
Ïåðåñäàëè àíàëèçû è îïÿòü ÑÐÁ -41. Êëèíèêà íîðì. Òåìïåðàòóðû íå áûëî òðè äíÿ è ñíîâà îíà âåðíóëàñü. Ïðè îñìîòðå òîëüêî øóìû â ñåðäöå. ß ïðî÷èòàëà ïðî ïîâûøåíèå ñðá, íî â íàøåì ñëó÷àå îí è íå ïîíèæàëñÿ ñ ëåòà (ïðî áîëüíè÷íûé ñðá ïèñàëà âûøå).
×òîáû óæå òî÷íî ïîíèìàòü âèðóñíàÿ ýòî èíôåêöèè èëè íåò, êàê íåîáõîäèìî îáñëåäîâàòü ðåáåíêà? Ïöð èç çåâà? åñòü ëè ñìûñë ãîñïèòàëèçèðîâàòüñÿ ñ äëèòåëüíûì ñóáôåáðèëèòåòîì è âûñîêèì ÑÐÁ? |
|
#8
|
||||
|
||||
íàïðèìåð, ïðè íåïîëíûõ ôîðìàõ PFAPA öèôðû ÖÐÁ íà ïèêå ôåáðèëüíîé Ò òåëà äîñòèãàþò 45-320 (â ñðåäíåì 65-70) è íàèâûñøèå öèôðû íà 2-4 äíè, ðåêîìåíäóþò èñêëþ÷àòü ýòîò ñèíäðîì ïðè ïåðèîä. ëèõîðàäêàõ ñ òàêèìè öèôðàìè ÑÐÁ è òàêèì ïàòòåðíîì:
In 16 children with PFAPA, a total of 87 CRP values were registered during 38 episodes of fever. The mean of the maximum CRP during each episode was 185 mg/L (SD: 69.4, range: 45-322). Values of CRP were elevated throughout the whole period of fever, with higher values on days 2-4 compared to day 1. High levels of CRP may suggest a role for immunological mechanisms in PFAPA, and may raise the suspicion of PFAPA when measured in children with periodic fever of unknown origin. --- Acta Paediatr. 2007 Nov;96(11):1670-3. C-reactive protein in the periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#9
|
||||
|
||||
1. Ñòîèò ñäàòü íà ïðîêàëüöèòîíèí.
2. Ñäåëàòü ÝÕÎ-Êà äëÿ èñêëþ÷åíèÿ ïîñòèíôåêöèîííîãî ìèîêàðäèòà. 3. Çíàþ, ÷òî öèñòîãðàôèþ ñäåëàåòå, äëÿ èñêëþ÷åíèÿ âûñîêîãî ÏÌÐ.
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷ |
#10
|
||||
|
||||
ïðè ãîñïèòàëèçàöèè âñåãäà âûøå ðèñê ïåðåêðåñòíîãî èíôèöèðîâàíèÿ( à ýòî îïÿòü ïîäüåì òåìåðàòóðû), ïîýòîìó äóìàþ ãîðàçäî ëó÷øå îáñëåäîâàòüñÿ àìáóëàòîðíî.
Åñëè áóäåòå ñäàâàòü êðîâü, ìîæåò ñòîèò ïðîâåðèòü íà ñëó÷àé ìàðêåðû íåñïåöåôè÷åñêèå àóòîèìóííûõ è ðåâìàòîëîãè÷åñêèõ çàáîëåâàíèé ANA,ANCA,complement. immunoglobulins , à òàê æå ìîæåò ñòîèò äîáàâèòü áèîõèìèþ,âêëþ÷àÿ ALT,AST,ALP,LDH,albumin... |
#11
|
|||
|
|||
Áîëüøîå âàì âñåì ñïàñèáî!
|
#12
|
|||
|
|||
Äà, ñîáèðàåìñÿ íà öèñòîãðàôèþ. Â÷åðà ñäåëàëè åùå ðàç óçè ïî÷åê. Ëîõàíêà ñ îäíîé ñòîðîíû 8 ñ äðóãîé 6. Êîãäà â áîëüíèöå ñìîòðåëè ïî÷êè, áûëî âñå íîðì
|
#13
|
||||
|
||||
à áûëè êîãäà òî ÈÌÏ?
|
#14
|
|||
|
|||
|